AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

NASDAQ:RCMR1 RCM Stock Price, Forecast & News

$12.26
-0.15 (-1.21 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.19
Now: $12.26
$12.63
50-Day Range
$10.18
MA: $11.25
$13.20
52-Week Range
$7.12
Now: $12.26
$13.99
Volume818,700 shs
Average Volume1.10 million shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.53
R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves healthcare providers, including health systems and hospitals, physicians groups, and municipal and private emergency medical service providers, as well as intermountain homecare, hospice and palliative care, and durable medical equipment and infusion therapy business. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.
Read More
R1 RCM logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.66 out of 5 stars


Industry, Sector and Symbol

Industry Management services
Sub-IndustryHealth Care Services
SectorFinance
Current SymbolNASDAQ:RCM
CUSIP00438V10
Phone312-324-7820

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 billion
Cash Flow$0.61 per share
Book Value$0.16 per share

Profitability

Net Income$12 million

Miscellaneous

Employees22,500
Market Cap$1.41 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive RCM News and Ratings via Email

Sign-up to receive the latest news and ratings for RCM and its competitors with MarketBeat's FREE daily newsletter.

R1 RCM (NASDAQ:RCM) Frequently Asked Questions

How has R1 RCM's stock been impacted by COVID-19 (Coronavirus)?

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RCM stock has increased by 20.7% and is now trading at $12.26. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of R1 RCM?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for R1 RCM.

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for R1 RCM.

How were R1 RCM's earnings last quarter?

R1 RCM Inc (NASDAQ:RCM) issued its quarterly earnings data on Tuesday, May, 5th. The healthcare provider reported $0.05 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.03. The healthcare provider had revenue of $320.50 million for the quarter, compared to analysts' expectations of $318.76 million. R1 RCM had a return on equity of 174.42% and a net margin of 2.44%. R1 RCM's revenue was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.04) EPS. View R1 RCM's earnings history.

What price target have analysts set for RCM?

6 analysts have issued 12-month price targets for R1 RCM's stock. Their forecasts range from $10.00 to $17.00. On average, they expect R1 RCM's share price to reach $13.83 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price. View analysts' price targets for R1 RCM.

Has R1 RCM been receiving favorable news coverage?

Media coverage about RCM stock has trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. R1 RCM earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned news coverage about the healthcare provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about R1 RCM.

Are investors shorting R1 RCM?

R1 RCM saw a decline in short interest in June. As of June 30th, there was short interest totaling 3,280,000 shares, a decline of 19.8% from the June 15th total of 4,090,000 shares. Based on an average daily volume of 1,090,000 shares, the short-interest ratio is presently 3.0 days. Currently, 3.0% of the company's stock are short sold. View R1 RCM's Current Options Chain.

Who are some of R1 RCM's key competitors?

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), Alibaba Group (BABA), JD.Com (JD), Baozun (BZUN), Marvell Technology Group (MRVL), Model N (MODN), Baidu (BIDU), BioDelivery Sciences International (BDSI), Perficient (PRFT) and RingCentral (RNG).

Who are R1 RCM's key executives?

R1 RCM's management team includes the following people:
  • Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 48)
  • Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 49)
  • Mr. Richard B. Evans Jr., Sr. VP, Interim CFO, Corp. Controller & Chief Accounting Officer (Age 51)
  • Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.
  • Mr. Corey Perman, Exec. VP of Compliance & Risk

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.02%) and Diversified Trust Co (0.02%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli, Charles J Ditkoff and Joseph Gerard Flanagan. View institutional ownership trends for R1 RCM.

Which institutional investors are selling R1 RCM stock?

RCM stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for R1 RCM.

Which institutional investors are buying R1 RCM stock?

RCM stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan. View insider buying and selling activity for R1 RCM.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $12.26.

How big of a company is R1 RCM?

R1 RCM has a market capitalization of $1.41 billion and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis. R1 RCM employs 22,500 workers across the globe.

What is R1 RCM's official website?

The official website for R1 RCM is www.r1rcm.com.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at 312-324-7820 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.